Ascletis Pharma Inc. (HKG:1672)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
8.61
-0.49 (-5.38%)
Jun 27, 2025, 4:08 PM HKT
912.94%
Market Cap 8.29B
Revenue (ttm) 1.37M
Net Income (ttm) -320.25M
Shares Out 962.85M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,790,679
Average Volume 6,868,843
Open 9.11
Previous Close 9.10
Day's Range 8.56 - 9.30
52-Week Range 0.76 - 11.20
Beta 0.36
RSI 50.71
Earnings Date Aug 21, 2025

About Ascletis Pharma

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of prima... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 231
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1672
Full Company Profile

Financial Performance

In 2024, Ascletis Pharma's revenue was 1.28 million, a decrease of -97.73% compared to the previous year's 56.60 million. Losses were -300.94 million, 108.0% more than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.